Gastroenterologists, payers possibly thwarting biosimilar adaptation — 4 key notes

Written by Eric Oliver | August 29, 2017 | Print  |

RealTime Dynamix analysts believe gastroenterologists and payers may thwart the widespread adaptation of biosimilars.

Here's what you should know:

1. Approximately 103 gastroenterologists reported declining Remicade use since 2016. RTD analysts attribute this decline to gastroenterologists placing patients on Humira to avoid payer mandates related to biosimilar use.

2. Thirty-three percent of respondents indicated if a payer recommends Inflectra over Remicade, they'd likely choose an alternate TNF-inhibitor. However, only 20 percent of respondents said a payer advised them as such.

3. Gastroenterologists noted payer mandates on biosimilars were stopping mass adaptation. However, RTD analysts believe payers will be forced to cover biosimilars, once more biosimilars emerge on the market and offer cheaper alternatives to the drugs.

4. RTD analysts believe future oral treatments currently in the pipeline have the potential to allow for widespread access to the drugs.

More articles on gastroenterology:
Florida jury finds gastroenterologist not liable in alleged 'slapdash colonoscopy' trial — 6 insights
Contaminated scopes used in 500+ patients at Buffalo VA
Renewed interest in gastroparesis research brings cure into focus 

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.